Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Insomnia Market, by Distribution Channel
1.4.2 LAMEA Insomnia Market, by Therapy Type
1.4.3 LAMEA Insomnia Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Insomnia Market
Chapter 4. LAMEA Insomnia Market by Distribution Channel
4.1 LAMEA Hospital Market by Country
4.2 LAMEA Retail Market by Country
4.3 LAMEA Others Market by Country
Chapter 5. LAMEA Insomnia Market by Therapy Type
5.1 LAMEA Pharmacological Market by Country
5.2 LAMEA Non-Pharmacological Market by Country
Chapter 6. LAMEA Insomnia Market by Country
6.1 Brazil Insomnia Market
6.1.1 Brazil Insomnia Market by Distribution Channel
6.1.2 Brazil Insomnia Market by Therapy Type
6.2 Argentina Insomnia Market
6.2.1 Argentina Insomnia Market by Distribution Channel
6.2.2 Argentina Insomnia Market by Therapy Type
6.3 UAE Insomnia Market
6.3.1 UAE Insomnia Market by Distribution Channel
6.3.2 UAE Insomnia Market by Therapy Type
6.4 Saudi Arabia Insomnia Market
6.4.1 Saudi Arabia Insomnia Market by Distribution Channel
6.4.2 Saudi Arabia Insomnia Market by Therapy Type
6.5 South Africa Insomnia Market
6.5.1 South Africa Insomnia Market by Distribution Channel
6.5.2 South Africa Insomnia Market by Therapy Type
6.6 Nigeria Insomnia Market
6.6.1 Nigeria Insomnia Market by Distribution Channel
6.6.2 Nigeria Insomnia Market by Therapy Type
6.7 Rest of LAMEA Insomnia Market
6.7.1 Rest of LAMEA Insomnia Market by Distribution Channel
6.7.2 Rest of LAMEA Insomnia Market by Therapy Type
Chapter 7. Company Profiles
7.1 Eisai Co., Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Product Launches and Product Expansions:
7.1.5.2 Approvals and Trails:
7.2 Takeda Pharmaceutical Company Limited
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Approvals and Trails:
7.3 Vanda Pharmaceuticals, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.3.4 Recent strategies and developments:
7.3.4.1 Approval and Trails:
7.4 Cadila Healthcare Ltd. (Zydus Cadila)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Sanofi S.A.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Geographical Expansions:
7.6 Merck Group
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Pfizer, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional & Segmental Analysis
7.7.4 Research & Development Expense
7.8 Viatris, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Acquisition and Mergers:
7.9.2.2 Geographical Expansions:
7.10. Purdue Pharma L.P.
7.10.1 Company Overview
Unique Offerings 